FIBROBLAST GROWTH FACTOR TYPE 1 AND 2 IN THE SERUM AT A PRIMARY MALIGNANT BONE TUMOR

Results of comparative evaluation of type 1 and 2 fibroblast growth factors (FGF-1, FGF-2) content in blood serum of 26 practically healthy persons (control group) and 105 untreated primary bone tumor patients are presented. No independent value of serum FGF-1 and FGF-2 for pre-surgical diagnostics of bone neoplasms was revealed. FGF-1 was significantly more frequently found in bone sarcomas patients than in healthy persons sera (65.7% and 26.9% respectively; р < 0.0001). Serum FGF-1 may be regarded as an unfavorable prognostic marker of typical osteosarcoma: 5-years overall survival of such patients with detectable serum FGF-1 was 1.7 times lower than that of patients with negative serum FGF-1 (р = 0.019). It was also demonstrated that high serum levels of both FGF-1, and FGF-2 in Ewing sarcoma patients were associated with low overall survival. No associations between FGF-1 and FGF-2 serum levels and overall survival of chondrosarcoma patients were revealed.